Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 6/20 | 0.49 |
| ▸ | HRH2 | P25021 | 9/20 | 0.49 |
| ▸ | HRH1 | P35367 | 9/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.49 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7028501 | 0.91 | KCNA5 (0.47) | KCNA5HRH2HRH1HRH3ALDH1A1 | |
| SCHEMBL2967821 | 0.90 | KCNH2 (0.48) | KCNA5HRH2HRH1HRH3ALDH1A1 | |
| SCHEMBL5965670 | 0.85 | KCNA5 (0.44) | KCNA5HRH2HRH1HRH3ALDH1A1 | |
| SCHEMBL6096920 | 0.85 | ALDH1A1 (0.37) | KCNA5HRH2HRH1HRH3ALDH1A1 | |
| SCHEMBL2964375 | 0.84 | KCNH2 (0.54) | HRH2HRH1HRH3 | |
| SCHEMBL6094912 | 0.83 | KCNH2 (0.52) | ALDH1A1MAPT | |
| SCHEMBL6094907 | 0.83 | KCNH2 (0.52) | ALDH1A1MAPT | |
| SCHEMBL6095815 | 0.82 | GRIN1 (0.44) | HRH2HRH1HRH3GRIN1GRIN2B | |
| SCHEMBL6095817 | 0.82 | GRIN1 (0.44) | HRH2HRH1HRH3GRIN1GRIN2B | |
| SCHEMBL7250291 | 0.82 | HRH2 (0.43) | KCNA5HRH2HRH1HRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144914-B2 | 3,7-diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2006-12-05 | — | — | US | disclosed |
| EP-1360187-B1 | 3,7-DIAZABICYCLO(3.3.0)OCTANES AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2005-06-22 | — | — | EP | disclosed |
| US-20040053986-A1 | 3,7-Diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2004-03-18 | — | — | US | disclosed |
| EP-1360187-A1 | 3,7-DIAZABICYCLO(3.3.0)OCTANES AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2003-11-12 | — | — | EP | disclosed |
| WO-2002060902-A1 | 3,7-DIAZABICYCLO[3.3.0]OCTANES AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053986-A1 | 3,7-Diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias | KCNH1, KCNH2, CACNA1E | KCNA5 46/4885HRH2 2122/4885HRH1 2707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.